49 research outputs found

    ΠšΠ»ΠΈΠ½ΠΈΡ‡Π΅ΡΠΊΠΈΠ΅ аспСкты послСопСрационного ΠΏΠ΅Ρ€ΠΈΡ‚ΠΎΠ½ΠΈΡ‚Π°, Ρ€Π°Π·Π²ΠΈΠ²ΡˆΠ΅Π³ΠΎΡΡ послС цистэктомии

    Get PDF
    Background. Surgical morbidities of radical cystectomy, which are, as a rule, complicated intraabdominal infections, appear to be the main causes of repeated surgeries and fatal outcomes. The elimination of the infection Indus and an-timicrobic therapy are the currently accepted standard of treatment for postoperative peritonitis in cancer urology, as well as in general surgery hospital.Objective: defining the most reasonable option of surgical aid for peritonitis developing after cystectomy.Materials and methods. In the time period from 2000 through 2014, 58 cancer patients with postoperative peritonitis developing after cystectomy received indoor treatment at N.N. Alexandrov Republican Research and Practical Center for Oncology and Medical Radiology. Their mean age was 64.9 years, the range 44-90 years, 53 (91.4 %) of them being male. Primary urinary bladder cancer was present in 51 (87.9 %) patients. Peritoneal infection was microbiologically verified in 57 (98.3 %) patients. Each case of fatal outcome was associated with ineffective treatment of peritonitis. Depending on the intraoperative findings (presence or absence of a hollow organ defect) and the surgical approach undertaken (obstructive resection or operation maintaining the continuity of the intestinal and/or urinary tract), the patients were stratified into three groups: group 1 (n = 28), group 2 (n = 20) and group 3 (n = 10). There were no significant differences in the basic parameters specifying peritoneal infection severity between the patients of groups 1 and 2 vs group 3 (p >0.05).Results. Overall mortality amounted to 25.9 %, 15 patients died. Among the 28 (48.3 %) patients (group 1) who underwent obstructive elimination of the peritonitis focus by means of urointestinal reservoir ablation, resection of small or large intestine with ileo- or colostomy, 6 patients died, mortality 21.4 %. In the 10 (17.2 %) patients (group 3) who succeeded in preserving the urinary conduit or continuity of the bowels by anastomosis defect closure, resection of enteroentero-anastomosis or urointestinal reservoir with repeated anastomosing or defect closure, mortality was higher (60 %) (p = 0.045); 6 patients died.Conclusion. The most effective option of surgical treatment of postoperative peritonitis developing after cystectomy is obstructive reoperation on the bowels and urinary tracts: compared with the intervention consisting in preserving the urinary conduit and/or continuity of the intestinal tract, this type of surgery caused a 2.8-fold lower mortality.Π’Π²Π΅Π΄Π΅Π½ΠΈΠ΅. Π₯ирургичСскиС ослоТнСния Ρ€Π°Π΄ΠΈΠΊΠ°Π»ΡŒΠ½ΠΎΠΉ цистэктомии, Ρ‚Π°ΠΊΠΈΠ΅ ΠΊΠ°ΠΊ ослоТнСнныС ΠΈΠ½Ρ‚Ρ€Π°Π°Π±Π΄ΠΎΠΌΠΈΠ½Π°Π»ΡŒΠ½Ρ‹Π΅ ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΈ ΠΈ ΠΊΠΈΡˆΠ΅Ρ‡Π½Π°Ρ Π½Π΅ΠΏΡ€ΠΎΡ…ΠΎΠ΄ΠΈΠΌΠΎΡΡ‚ΡŒ, - основныС ΠΏΡ€ΠΈΡ‡ΠΈΠ½Ρ‹ ΠΏΠΎΠ²Ρ‚ΠΎΡ€Π½Ρ‹Ρ… ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΠΉ ΠΈ Π»Π΅Ρ‚Π°Π»ΡŒΠ½Ρ‹Ρ… исходов. ΠžΠ±Ρ‰Π΅ΠΏΡ€ΠΈΠ½ΡΡ‚Ρ‹ΠΌ стандартом лСчСния послСопСрационного ΠΏΠ΅Ρ€ΠΈΡ‚ΠΎΠ½ΠΈΡ‚Π° Π² ΠΎΠ½ΠΊΠΎΡƒΡ€ΠΎΠ»ΠΎΠ³ΠΈΠΈ, ΠΊΠ°ΠΊ ΠΈ Π² общСхирургичСском стационарС, ΡΠ²Π»ΡΡŽΡ‚ΡΡ устранСниС ΠΎΡ‡Π°Π³Π° ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΈ ΠΈ антимикробная тСрапия.ЦСль исслСдования - ΠΎΠΏΡ€Π΅Π΄Π΅Π»ΠΈΡ‚ΡŒ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΠΏΡ€ΠΈΠ΅ΠΌΠ»Π΅ΠΌΡ‹ΠΉ Π²Π°Ρ€ΠΈΠ°Π½Ρ‚ хирургичСского пособия ΠΏΡ€ΠΈ ΠΏΠ΅Ρ€ΠΈΡ‚ΠΎΠ½ΠΈΡ‚Π΅, Ρ€Π°Π·Π²ΠΈΠ²ΡˆΠ΅ΠΌΡΡ послС цистэктомии.ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Ρ‹ ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹. Π’ ΠΏΠ΅Ρ€ΠΈΠΎΠ΄ с 2000 ΠΏΠΎ 2014 Π³. Π² РСспубликанском Π½Π°ΡƒΡ‡Π½ΠΎ-практичСском Ρ†Π΅Π½Ρ‚Ρ€Π΅ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈ мСдицинской Ρ€Π°Π΄ΠΈΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈΠΌ. Н.Н. АлСксандрова Π½Π° стационарном Π»Π΅Ρ‡Π΅Π½ΠΈΠΈ Π½Π°Ρ…ΠΎΠ΄ΠΈΠ»ΠΈΡΡŒ 58 онкологичСских ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² (ΠΈΠ· Π½ΠΈΡ… 53 (91,4 %) ΠΌΡƒΠΆΡ‡ΠΈΠ½Ρ‹) с послСопСрационным ΠΏΠ΅Ρ€ΠΈΡ‚ΠΎΠ½ΠΈΡ‚ΠΎΠΌ, ΠΊΠΎΡ‚ΠΎΡ€Ρ‹ΠΉ развился послС цистэктомии. Π‘Ρ€Π΅Π΄Π½ΠΈΠΉ возраст - 64,9 (44-90) Π³ΠΎΠ΄Π°. ΠŸΠ΅Ρ€Π²ΠΈΡ‡Π½Ρ‹ΠΉ Ρ€Π°ΠΊ ΠΌΠΎΡ‡Π΅Π²ΠΎΠ³ΠΎ пузыря зарСгистрирован Ρƒ 51 (87,9 %) ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Π°. ΠœΠΈΠΊΡ€ΠΎΠ±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡ‡Π΅ΡΠΊΠΎΠ΅ ΠΏΠΎΠ΄Ρ‚Π²Π΅Ρ€ΠΆΠ΄Π΅Π½ΠΈΠ΅ ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΈ Π±Ρ€ΡŽΡˆΠΈΠ½Ρ‹ имСлось Ρƒ 57 (98,3 %) ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ². ΠšΠ°ΠΆΠ΄Ρ‹ΠΉ случай Π»Π΅Ρ‚Π°Π»ΡŒΠ½ΠΎΠ³ΠΎ исхода ассоциирован с Π½Π΅ΡΡ„Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒΡŽ лСчСния ΠΏΠ΅Ρ€ΠΈΡ‚ΠΎΠ½ΠΈΡ‚Π°. Π’ зависимости ΠΎΡ‚ ΠΈΠ½Ρ‚Ρ€Π°ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΠΎΠ½Π½Ρ‹Ρ… Π΄Π°Π½Π½Ρ‹Ρ… (Π½Π°Π»ΠΈΡ‡ΠΈΠ΅ ΠΈΠ»ΠΈ отсутствиС Π΄Π΅Ρ„Π΅ΠΊΡ‚Π° ΠΏΠΎΠ»ΠΎΠ³ΠΎ ΠΎΡ€Π³Π°Π½Π°) ΠΈ прСдпринятой хирургичСской Ρ‚Π°ΠΊΡ‚ΠΈΠΊΠΈ (обструктивная рСзСкция ΠΈΠ»ΠΈ опСрация с сохранСниСм нСпрСрывности ΠΊΠΈΡˆΠ΅Ρ‡Π½ΠΎΠ³ΠΎ ΠΈ/ΠΈΠ»ΠΈ ΠΌΠΎΡ‡Π΅Π²ΠΎΠ³ΠΎ Ρ‚Ρ€Π°ΠΊΡ‚Π°) ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Ρ‹ Π±Ρ‹Π»ΠΈ стратифицированы Π½Π° 3 Π³Ρ€ΡƒΠΏΠΏΡ‹: Π² 1-ю Π³Ρ€ΡƒΠΏΠΏΡƒ вошли 28 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ², Π²ΠΎ 2-ю - 20, Π² 3-ю - 10. БущСствСнных Ρ€Π°Π·Π»ΠΈΡ‡ΠΈΠΉ ΠΏΠΎ основным ΠΏΠ°Ρ€Π°ΠΌΠ΅Ρ‚Ρ€Π°ΠΌ, Ρ…Π°Ρ€Π°ΠΊΡ‚Π΅Ρ€ΠΈΠ·ΡƒΡŽΡ‰ΠΈΠΌ Ρ‚ΡΠΆΠ΅ΡΡ‚ΡŒ ΠΏΠ΅Ρ€ΠΈΡ‚ΠΎΠ½Π΅Π°Π»ΡŒΠ½ΠΎΠΉ ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΈ, срСди ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² 1-ΠΉ ΠΈ 2-ΠΉ Π³Ρ€ΡƒΠΏΠΏ ΠΏΠΎ ΡΡ€Π°Π²Π½Π΅Π½ΠΈΡŽ с 3-ΠΉ Π½Π΅ Π±Ρ‹Π»ΠΎ (Ρ€ >0,05).Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. ΠžΠ±Ρ‰Π°Ρ Π»Π΅Ρ‚Π°Π»ΡŒΠ½ΠΎΡΡ‚ΡŒ составила 25,9 %; ΡƒΠΌΠ΅Ρ€Π»ΠΈ 15 Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊ. Π‘Ρ€Π΅Π΄ΠΈ 28 (48,3 %) ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² 1-ΠΉ Π³Ρ€ΡƒΠΏΠΏΡ‹, ΠΊΠΎΡ‚ΠΎΡ€Ρ‹ΠΌ Π»ΠΈΠΊΠ²ΠΈΠ΄Π°Ρ†ΠΈΡŽ источника ΠΏΠ΅Ρ€ΠΈΡ‚ΠΎΠ½ΠΈΡ‚Π° ΠΏΡ€ΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ ΠΏΠΎ обструктивному Ρ‚ΠΈΠΏΡƒ ΠΏΡƒΡ‚Π΅ΠΌ удалСния ΠΌΠΎΡ‡Π΅ΠΊΠΈΡˆΠ΅Ρ‡Π½ΠΎΠ³ΠΎ Ρ€Π΅Π·Π΅Ρ€Π²ΡƒΠ°Ρ€Π°, Ρ€Π΅Π·Π΅ΠΊΡ†ΠΈΠ΅ΠΉ Ρ‚ΠΎΠ½ΠΊΠΎΠ³ΠΎ ΠΈΠ»ΠΈ толстого ΠΊΠΈΡˆΠ΅Ρ‡Π½ΠΈΠΊΠ° с ΠΈΠ»Π΅ΠΎ- ΠΈΠ»ΠΈ колостомиСй, ΡƒΠΌΠ΅Ρ€Π»ΠΈ 6 Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊ; Π»Π΅Ρ‚Π°Π»ΡŒΠ½ΠΎΡΡ‚ΡŒ - 21,4 %. Из 10 (17,2 %) ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² 3-ΠΉ Π³Ρ€ΡƒΠΏΠΏΡ‹, ΠΊΠΎΡ‚ΠΎΡ€Ρ‹ΠΌ ΡƒΠ΄Π°Π»ΠΎΡΡŒ ΡΠΎΡ…Ρ€Π°Π½ΠΈΡ‚ΡŒ ΠΌΠΎΡ‡Π΅Π²ΠΎΠΉ ΠΊΠΎΠ½Π΄ΡƒΠΈΡ‚ ΠΈΠ»ΠΈ Π½Π΅ΠΏΡ€Π΅Ρ€Ρ‹Π²Π½ΠΎΡΡ‚ΡŒ ΠΊΠΈΡˆΠ΅Ρ‡Π½ΠΈΠΊΠ° ΡƒΡˆΠΈΠ²Π°Π½ΠΈΠ΅ΠΌ Π΄Π΅Ρ„Π΅ΠΊΡ‚Π° Π² анастомозС, Ρ€Π΅Π·Π΅ΠΊΡ†ΠΈΠ΅ΠΉ ΠΌΠ΅ΠΆΠΊΠΈΡˆΠ΅Ρ‡Π½ΠΎΠ³ΠΎ ΡΠΎΡƒΡΡ‚ΡŒΡ ΠΈΠ»ΠΈ ΠΌΠΎΡ‡Π΅ΠΊΠΈΡˆΠ΅Ρ‡Π½ΠΎΠ³ΠΎ Ρ€Π΅Π·Π΅Ρ€Π²ΡƒΠ°Ρ€Π° с ΠΏΠΎΠ²Ρ‚ΠΎΡ€Π½Ρ‹ΠΌ анастомозированиСм ΠΈΠ»ΠΈ ΡƒΡˆΠΈΠ²Π°Π½ΠΈΠ΅ΠΌ Π΄Π΅Ρ„Π΅ΠΊΡ‚Π°, Π»Π΅Ρ‚Π°Π»ΡŒΠ½ΠΎΡΡ‚ΡŒ Π±Ρ‹Π»Π° Π²Ρ‹ΡˆΠ΅ - 60 % (Ρ€ = 0,045); ΡƒΠΌΠ΅Ρ€Π»ΠΈ 6 Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊ.Π—Π°ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅. НаиболСС Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚ΠΈΠ²Π½Ρ‹ΠΌ Π²Π°Ρ€ΠΈΠ°Π½Ρ‚ΠΎΠΌ хирургичСского лСчСния послСопСрационного ΠΏΠ΅Ρ€ΠΈΡ‚ΠΎΠ½ΠΈΡ‚Π°, Ρ€Π°Π·Π²ΠΈΠ²ΡˆΠ΅Π³ΠΎΡΡ послС цистэктомии, являСтся обструктивная рСопСрация Π½Π° ΠΊΠΈΡˆΠ΅Ρ‡Π½ΠΈΠΊΠ΅ ΠΈ ΠΌΠΎΡ‡Π΅Π²Ρ‹Ρ… путях. По ΡΡ€Π°Π²Π½Π΅Π½ΠΈΡŽ с Π²ΠΌΠ΅ΡˆΠ°Ρ‚Π΅Π»ΡŒΡΡ‚Π²ΠΎΠΌ, состоящим Π² сохранСнии ΠΌΠΎΡ‡Π΅Π²ΠΎΠ³ΠΎ ΠΊΠΎΠ½Π΄ΡƒΠΈΡ‚Π° ΠΈ/ΠΈΠ»ΠΈ нСпрСрывности ΠΊΠΈΡˆΠ΅Ρ‡Π½ΠΎΠ³ΠΎ Ρ‚Ρ€Π°ΠΊΡ‚Π°, ΠΏΡ€ΠΈ Π΄Π°Π½Π½ΠΎΠΌ Ρ‚ΠΈΠΏΠ΅ ΠΎΠΏΠ΅Ρ€Π°Ρ†ΠΈΠΈ Π»Π΅Ρ‚Π°Π»ΡŒΠ½ΠΎΡΡ‚ΡŒ Π±Ρ‹Π»Π° Π² 2,8 Ρ€Π°Π·Π° Π½ΠΈΠΆΠ΅

    OPEN XAL Status Report 2015

    Get PDF
    MOPW1050International audienceOpen XAL is an accelerator physics software platformdeveloped in collaboration among several facilitiesaround the world. The Open XAL collaboration wasformed in 2010 to port, improve and extend the successfulXAL platform used at the Spallation Neutron Source foruse in the broader accelerator community and to establishit as the standard platform for accelerator physicssoftware. The site-independent core is complete, activeapplications have been ported, and now we are in theprocess of verification and transitioning to using OpenXAL in production. This paper will present the currentstatus and a roadmap for this project

    Open XAL status Report 2015

    Get PDF
    Open XAL is an accelerator physics software platform developed in collaboration among several facilities around the world. The Open XAL collaboration was formed in 2010 to port, improve and extend the successful XAL platform used at the Spallation Neutron Source for use in the broader accelerator community and to establish it as the standard platform for accelerator physics software. The site-independent core is complete, active applications have been ported, and now we are in the process of verification and transitioning to using Open XAL in production. This paper will present the current status and a roadmap for this project

    Π§ΡƒΠ²ΡΡ‚Π²ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΡŒ ΠΊ Π³Π»ΡŽΠΊΠΎΠΊΠΎΡ€Ρ‚ΠΈΠΊΠΎΡΡ‚Π΅Ρ€ΠΎΠΈΠ΄Π°ΠΌ ΠΈ Π³Π΅Ρ‚Π΅Ρ€ΠΎΠ³Π΅Π½Π½ΠΎΡΡ‚ΡŒ ΠΎΡ‚Π²Π΅Ρ‚Π° ΠΊΠ»Π΅Ρ‚ΠΎΠΊ in vitro Ρƒ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с хроничСской обструктивной болСзнью Π»Π΅Π³ΠΊΠΈΡ…

    Get PDF
    Inhaled corticosteroids are widely used for the treatment of chronic obstructive pulmonary disease (COPD), but their efficacy significantly varies between patients. The aim of the study was to establish approaches to reveal steroid-sensitive and steroid-resistant patients with COPD using the blood and lung cells. Methods. Forty five patients with COPD undergoing bronchoscopy were recruited for the study of cytokine secretion by alveolar macrophages under the influence of glucocorticoids. Alveolar macrophages isolated from bronchoalveolar lavage fluid were cultured with lipopolysaccharide (LPS) and different concentrations of dexamethasone (0.01 – 1000 nM) for 24 h. Then, supernatants were removed and analyzed for concentrations of interleukin 6 (IL-6), IL-8 and tumor necrosis factor Ξ± (TNF-Ξ±). Binding of the glucocorticoid with its receptors was investigated in 24 patients with COPD, 20 healthy smokers and 20 healthy non-smokers. Blood cells were cultured with fluorescein isothiocyanate (FITC)-labelled dexamethasone and monoclonal antibodies against surface antigens of lymphocyte and monocyte populations. Fluorescence intensity of FITC-labelled dexamethasone was analyzed in blood cells using flow cytometry. Results. Dexamethasone significantly inhibited IL-6, IL-8, and TNF-Ξ± production in alveolar macrophages in a dose dependent manner. The maximal inhibition of cytokine production was observed at dexamethasone concentration of 100 nM, and the maximal cell response variability was found at 10 nM. IL-8 was less sensitive to the corticosteroid compared to IL-6 and TNF-Ξ±. Dexamethasone at any concentration failed to reach >50% inhibition of LPS-induced production of IL-8, IL-6 and TNF-Ξ± in alveolar macrophages of 40.0%; 11.1% and 8.9% of COPD patients, respectively. The fluorescence intensity of FITC-labelled dexamethasone in blood lymphocytes and monocytes was lower in smokers with COPD compared to healthy smokers and healthy non-smokers. The binding of dexamethasone with its receptors in the blood cells was higher in healthy non-smokers compared to healthy smokers. Conclusion. In vitro response of alveolar macrophages to glucocorticoids in COPD patients is characterized by significant inter-individual variability. The weak corticosteroid-related inhibition of IL-8 production can contribute to neutrophilic inflammation in COPD. The capacity of glucocorticoid receptors to bind with their ligands in blood lymphocytes and monocytes is decreased in COPD patients.Π˜Π½Π³Π°Π»ΡΡ†ΠΈΠΎΠ½Π½Ρ‹Π΅ Π³Π»ΡŽΠΊΠΎΠΊΠΎΡ€Ρ‚ΠΈΠΊΠΎΡΡ‚Π΅Ρ€ΠΎΠΈΠ΄Ρ‹ (ΠΈΠ“ΠšΠ‘) ΡˆΠΈΡ€ΠΎΠΊΠΎ ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΡƒΡŽΡ‚ΡΡ для лСчСния ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с хроничСской обструктивной болСзнью Π»Π΅Π³ΠΊΠΈΡ… (Π₯ΠžΠ‘Π›), ΠΎΠ΄Π½Π°ΠΊΠΎ ΠΈΡ… ΡΡ„Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ Π·Π½Π°Ρ‡ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎ различаСтся. ЦСлью настоящСго исслСдования явилось ΠΎΠΏΡ€Π΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΏΠΎΠ΄Ρ…ΠΎΠ΄ΠΎΠ² ΠΊ Π²Ρ‹ΡΠ²Π»Π΅Π½ΠΈΡŽ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с Π₯ΠžΠ‘Π›, Ρ‡ΡƒΠ²ΡΡ‚Π²ΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹Ρ… ΠΈ Π½Π΅Ρ‡ΡƒΠ²ΡΡ‚Π²ΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹Ρ… ΠΊ Π“ΠšΠ‘, ΠΏΡ€ΠΈ использовании ΠΊΠ»Π΅Ρ‚ΠΎΠΊ Π»Π΅Π³ΠΊΠΈΡ… ΠΈ ΠΊΡ€ΠΎΠ²ΠΈ. ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Ρ‹ ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹. Π’ исслСдовании Ρ†ΠΈΡ‚ΠΎΠΊΠΈΠ½-ΡΠ΅ΠΊΡ€Π΅Ρ‚ΠΈΡ€ΡƒΡŽΡ‰Π΅ΠΉ Ρ„ΡƒΠ½ΠΊΡ†ΠΈΠΈ Π°Π»ΡŒΠ²Π΅ΠΎΠ»ΡΡ€Π½Ρ‹Ρ… ΠΌΠ°ΠΊΡ€ΠΎΡ„Π°Π³ΠΎΠ² (АМ) ΠΏΠΎΠ΄ влияниСм Π“ΠšΠ‘ приняли участиС ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Ρ‹ (n = 45), ΠΊΠΎΡ‚ΠΎΡ€Ρ‹ΠΌ Π²Ρ‹ΠΏΠΎΠ»Π½ΡΠ»Π°ΡΡŒ бронхоскопия. АМ, Π²Ρ‹Π΄Π΅Π»Π΅Π½Π½Ρ‹Π΅ ΠΈΠ· Π±Ρ€ΠΎΠ½Ρ…ΠΎΠ°Π»ΡŒΠ²Π΅ΠΎΠ»ΡΡ€Π½ΠΎΠΉ Π»Π°Π²Π°ΠΆΠ½ΠΎΠΉ Тидкости, ΠΊΡƒΠ»ΡŒΡ‚ΠΈΠ²ΠΈΡ€ΠΎΠ²Π°Π»ΠΈΡΡŒ с липополисахаридом ΠΈ Ρ€Π°Π·Π»ΠΈΡ‡Π½Ρ‹ΠΌΠΈ концСнтрациями дСксамСтазона (0,01–1Β 000 нМ). По истСчСнии 1 суток ΡΠΎΠ±ΠΈΡ€Π°Π»ΠΈΡΡŒ супСрнатанты, Π² Π½ΠΈΡ… ΠΎΠΏΡ€Π΅Π΄Π΅Π»ΡΠ»Π°ΡΡŒ концСнтрация ΠΈΠ½Ρ‚Π΅Ρ€Π»Π΅ΠΉΠΊΠΈΠ½Π° (IL)-6, IL-8 ΠΈ Ρ„Π°ΠΊΡ‚ΠΎΡ€Π° Π½Π΅ΠΊΡ€ΠΎΠ·Π° ΠΎΠΏΡƒΡ…ΠΎΠ»ΠΈ-Ξ± (TNF-Ξ±). Для изучСния особСнностСй взаимодСйствия Π“ΠšΠ‘ ΠΈ ΠΈΡ… Ρ€Π΅Ρ†Π΅ΠΏΡ‚ΠΎΡ€ΠΎΠ² обслСдованы ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Ρ‹ с Π₯ΠžΠ‘Π› (n = 24), Π·Π΄ΠΎΡ€ΠΎΠ²Ρ‹Π΅ ΠΊΡƒΡ€ΠΈΠ»ΡŒΡ‰ΠΈΠΊΠΈ (n = 20) ΠΈ Π·Π΄ΠΎΡ€ΠΎΠ²Ρ‹Π΅ нСкурящиС (n = 20). ΠšΠ»Π΅Ρ‚ΠΊΠΈ ΠΊΡ€ΠΎΠ²ΠΈ ΠΊΡƒΠ»ΡŒΡ‚ΠΈΠ²ΠΈΡ€ΠΎΠ²Π°Π»ΠΈΡΡŒ с дСксамСтазоном, ΠΌΠ΅Ρ‡Π΅Π½Π½Ρ‹ΠΌ Ρ„Π»ΡŽΠΎΡ€Π΅ΡΡ†Π΅ΠΈΠ½ΠΈΠ·ΠΎΡ‚ΠΈΠΎΡ†ΠΈΠ°Π½Π°Ρ‚ΠΎΠΌ (FITC) ΠΈ ΠΌΠΎΠ½ΠΎΠΊΠ»ΠΎΠ½Π°Π»ΡŒΠ½Ρ‹ΠΌΠΈ Π°Π½Ρ‚ΠΈΡ‚Π΅Π»Π°ΠΌΠΈ ΠΊ повСрхностным Π°Π½Ρ‚ΠΈΠ³Π΅Π½Π°ΠΌ популяций Π»ΠΈΠΌΡ„ΠΎΡ†ΠΈΡ‚ΠΎΠ² ΠΈ ΠΌΠΎΠ½ΠΎΡ†ΠΈΡ‚ΠΎΠ². Анализ интСнсивности Ρ„Π»ΡŽΠΎΡ€Π΅ΡΡ†Π΅Π½Ρ†ΠΈΠΈ FITC-ΠΌΠ΅Ρ‡Π΅Π½Π½ΠΎΠ³ΠΎ дСксамСтазона Π² ΠΊΠ»Π΅Ρ‚ΠΊΠ°Ρ… ΠΊΡ€ΠΎΠ²ΠΈ проводился с использованиСм ΠΏΡ€ΠΎΡ‚ΠΎΡ‡Π½ΠΎΠΉ Ρ†ΠΈΡ‚ΠΎΠΌΠ΅Ρ‚Ρ€ΠΈΠΈ. Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. ΠŸΡ€ΠΈ использовании дСксамСтазона дозозависимо сниТалась сСкрСция IL-6, IL-8 ΠΈ TNF-Ξ± АМ. МаксимальноС Π·Π½Π°Ρ‡Π΅Π½ΠΈΠ΅ ингибирования ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ†ΠΈΠΈ Ρ†ΠΈΡ‚ΠΎΠΊΠΈΠ½ΠΎΠ² АМ наблюдалось ΠΏΡ€ΠΈ ΠΊΠΎΠ½Ρ†Π΅Π½Ρ‚Ρ€Π°Ρ†ΠΈΠΈ дСксамСтазона 100 нМ, Π° наибольшая ΡΡ‚Π΅ΠΏΠ΅Π½ΡŒ Π²Π°Ρ€ΠΈΠ°Π±Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΠΈ ΠΎΡ‚Π²Π΅Ρ‚Π° ΠΊΠ»Π΅Ρ‚ΠΎΠΊ – ΠΏΡ€ΠΈ 10 нМ. IL-8 Π±Ρ‹Π» ΠΌΠ΅Π½Π΅Π΅ чувствитСлСн ΠΊ ΠΈΠ“ΠšΠ‘, Ρ‡Π΅ΠΌ IL-6 ΠΈ TNF-Ξ±. ΠŸΡ€ΠΈ любой ΠΈΠ· ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΡƒΠ΅ΠΌΡ‹Ρ… ΠΊΠΎΠ½Ρ†Π΅Π½Ρ‚Ρ€Π°Ρ†ΠΈΠΉ дСксамСтазон Π½Π΅ ΠΈΠ½Π³ΠΈΠ±ΠΈΡ€ΠΎΠ²Π°Π» Π±ΠΎΠ»Π΅Π΅ Ρ‡Π΅ΠΌ Π½Π° 50 % ΠΈΠ½Π΄ΡƒΡ†ΠΈΡ€ΠΎΠ²Π°Π½Π½ΡƒΡŽ ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ†ΠΈΡŽ IL-8 Π² АМ Ρƒ 40 % ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с Π₯ΠžΠ‘Π›, IL-6 – Ρƒ 11,1 %, TNF-Ξ± – Ρƒ 8,9 %. Π£ курящих ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с Π₯ΠžΠ‘Π› ΠΈΠ½Ρ‚Π΅Π½ΡΠΈΠ²Π½ΠΎΡΡ‚ΡŒ Ρ„Π»ΡŽΠΎΡ€Π΅ΡΡ†Π΅Π½Ρ†ΠΈΠΈ FITC-ΠΌΠ΅Ρ‡Π΅Π½Π½ΠΎΠ³ΠΎ дСксамСтазона Π² популяциях Π»ΠΈΠΌΡ„ΠΎΡ†ΠΈΡ‚ΠΎΠ² ΠΈ ΠΌΠΎΠ½ΠΎΡ†ΠΈΡ‚Π°Ρ… ΠΊΡ€ΠΎΠ²ΠΈ оказалась Π½ΠΈΠΆΠ΅, Ρ‡Π΅ΠΌ Ρƒ курящих ΠΈ нСкурящих Π·Π΄ΠΎΡ€ΠΎΠ²Ρ‹Ρ…. БвязываниС дСксамСтазона со своими Ρ€Π΅Ρ†Π΅ΠΏΡ‚ΠΎΡ€Π°ΠΌΠΈ Π² ΠΊΠ»Π΅Ρ‚ΠΊΠ°Ρ… ΠΊΡ€ΠΎΠ²ΠΈ Π±Ρ‹Π»ΠΎ Π²Ρ‹ΡˆΠ΅ Ρƒ нСкурящих Π·Π΄ΠΎΡ€ΠΎΠ²Ρ‹Ρ…, Ρ‡Π΅ΠΌ Ρƒ Π·Π΄ΠΎΡ€ΠΎΠ²Ρ‹Ρ… ΠΊΡƒΡ€ΠΈΠ»ΡŒΡ‰ΠΈΠΊΠΎΠ². Π—Π°ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅. Π₯ΠžΠ‘Π› характСризуСтся сущСствСнной ΠΌΠ΅ΠΆΠΈΠ½Π΄ΠΈΠ²ΠΈΠ΄ΡƒΠ°Π»ΡŒΠ½ΠΎΠΉ Π²Π°Ρ€ΠΈΠ°Π±Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΡŒΡŽ in vitro ΠΎΡ‚Π²Π΅Ρ‚Π° АМ Π½Π° Π“ΠšΠ‘. ΠžΠ³Ρ€Π°Π½ΠΈΡ‡Π΅Π½Π½ΠΎΠ΅ ΠΈΠ½Π³ΠΈΠ±ΠΈΡ€ΠΎΠ²Π°Π½ΠΈΠ΅ синтСза IL-8 Π“ΠšΠ‘ ΠΌΠΎΠΆΠ΅Ρ‚ ΡΠΏΠΎΡΠΎΠ±ΡΡ‚Π²ΠΎΠ²Π°Ρ‚ΡŒ ΠΏΠΎΠ΄Π΄Π΅Ρ€ΠΆΠ°Π½ΠΈΡŽ Π½Π΅ΠΉΡ‚Ρ€ΠΎΡ„ΠΈΠ»ΡŒΠ½ΠΎΠ³ΠΎ Ρ‚ΠΈΠΏΠ° воспалСния ΠΏΡ€ΠΈ Π₯ΠžΠ‘Π›. Для ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² с Π₯ΠžΠ‘Π› свойствСнно сниТСниС способности Π“ΠšΠ‘-Ρ€Π΅Ρ†Π΅ΠΏΡ‚ΠΎΡ€ΠΎΠ² ΡΠ²ΡΠ·Ρ‹Π²Π°Ρ‚ΡŒΡΡ со своими Π»ΠΈΠ³Π°Π½Π΄Π°ΠΌΠΈ Π² Π»ΠΈΠΌΡ„ΠΎΡ†ΠΈΡ‚Π°Ρ… ΠΈ ΠΌΠΎΠ½ΠΎΡ†ΠΈΡ‚Π°Ρ… ΠΊΡ€ΠΎΠ²ΠΈ

    ΠΠ›Π›ΠžΠ’Π ΠΠΠ‘ΠŸΠ›ΠΠΠ’ΠΠ¦Π˜Π― ΠΠ’Πž-ΠΠ•Π‘ΠžΠ’ΠœΠ•Π‘Π’Π˜ΠœΠ«Π₯ ΠŸΠžΠ§Π•Πš Π£ Π”Π•Π’Π•Π™

    Get PDF
    At present the problem of donor organs for transplantation shortage remains unsolved. Cautious and mixed attitude towards the transplantation of incompatible kidneys remains, while it could considerably reduce the donor organ waiting time for a recipient. Experience of 19 allotransplantations of ABO-incompatible kidneys in children is analyzed in the article. A group of 14 patients who received ABOcompatible kidneys was chosen for the comparative analysis. Such parameters as the assessment of function of allotransplanted kidneys, morphology character comparison of biopsy materials of allo-kidneys in both groups, actuarial survival rate of the recipients with functioning allografts are used to assess the results. Comparison of the aforementioned parameters showed practically the same results, and that enables us to assert that transplantations of kidneys of ABO-incompatible donors have the right to exist.Π’ настоящСС врСмя остаСтся Π½Π΅Ρ€Π΅ΡˆΠ΅Π½Π½ΠΎΠΉ ΠΏΡ€ΠΎΠ±Π»Π΅ΠΌΠ° Π½Π΅Ρ…Π²Π°Ρ‚ΠΊΠΈ донорских ΠΎΡ€Π³Π°Π½ΠΎΠ² для трансплантации. БохраняСтся настороТСнноС, Π½Π΅ΠΎΠ΄Π½ΠΎΠ·Π½Π°Ρ‡Π½ΠΎΠ΅ ΠΎΡ‚Π½ΠΎΡˆΠ΅Π½ΠΈΠ΅ ΠΊ пСрСсадкС нСсовмСстимых ΠΏΠΎΡ‡Π΅ΠΊ, ΠΏΡ€ΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Ρ… ΠΌΠΎΠ³Π»ΠΎ Π±Ρ‹ Π·Π½Π°Ρ‡ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎ ΡΠΎΠΊΡ€Π°Ρ‚ΠΈΡ‚ΡŒ врСмя оТидания Ρ€Π΅Ρ†ΠΈΠΏΠΈΠ΅Π½Ρ‚ΠΎΠΌ донорского ΠΎΡ€Π³Π°Π½Π°. Π’ ΡΡ‚Π°Ρ‚ΡŒΠ΅ ΠΏΡ€ΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡ€ΠΎΠ²Π°Π½ ΠΎΠΏΡ‹Ρ‚ 19 аллотрансплантаций АВ0-нСсовмСстимых ΠΏΠΎΡ‡Π΅ΠΊ Ρƒ Π΄Π΅Ρ‚Π΅ΠΉ. Для ΡΡ€Π°Π²Π½ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° Π²Ρ‹Π±Ρ€Π°Π½Π° Π³Ρ€ΡƒΠΏΠΏΠ° ΠΈΠ· 14 Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ…, ΠΊΠΎΡ‚ΠΎΡ€Ρ‹ΠΌ Π²Ρ‹ΠΏΠΎΠ»Π½Π΅Π½Ρ‹ пСрСсадки АВ0-совмСстимых ΠΏΠΎΡ‡Π΅ΠΊ. Для ΠΎΡ†Π΅Π½ΠΊΠΈ Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚ΠΎΠ² ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΠΎΠ²Π°Π½Ρ‹ Ρ‚Π°ΠΊΠΈΠ΅ ΠΏΠ°Ρ€Π°ΠΌΠ΅Ρ‚Ρ€Ρ‹, ΠΊΠ°ΠΊ ΠΎΡ†Π΅Π½ΠΊΠ° Ρ„ΡƒΠ½ΠΊΡ†ΠΈΠΈ аллотрансплантированных ΠΏΠΎΡ‡Π΅ΠΊ, сравнСниС Ρ…Π°Ρ€Π°ΠΊΡ‚Π΅Ρ€Π° ΠΌΠΎΡ€Ρ„ΠΎΠ»ΠΎΠ³ΠΈΠΈ Π±ΠΈΠΎΠΏΡ‚Π°Ρ‚ΠΎΠ² Π°Π»Π»ΠΎΠΏΠΎΡ‡Π΅ΠΊ Π² ΠΎΠ±Π΅ΠΈΡ… Π³Ρ€ΡƒΠΏΠΏΠ°Ρ…, ΠΎΡ†Π΅Π½ΠΊΠ° Π°ΠΊΡ‚ΡƒΠ°Ρ€Π½ΠΎΠΉ выТиваСмости Ρ€Π΅Ρ†ΠΈΠΏΠΈΠ΅Π½Ρ‚ΠΎΠ² с Ρ„ΡƒΠ½ΠΊΡ†ΠΈΠΎΠ½ΠΈΡ€ΡƒΡŽΡ‰ΠΈΠΌΠΈ аллотрансплантатами. Π‘Ρ€Π°Π²Π½Π΅Π½ΠΈΠ΅ Π²Ρ‹ΡˆΠ΅ΠΏΠ΅Ρ€Π΅Ρ‡ΠΈΡΠ»Π΅Π½Π½Ρ‹Ρ… ΠΏΠ°Ρ€Π°ΠΌΠ΅Ρ‚Ρ€ΠΎΠ² ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΎ практичСски ΠΎΠ΄ΠΈΠ½Π°ΠΊΠΎΠ²Ρ‹Π΅ Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹, Ρ‡Ρ‚ΠΎ Π΄Π°Π΅Ρ‚ Π½Π°ΠΌ ΠΏΡ€Π°Π²ΠΎ ΡƒΡ‚Π²Π΅Ρ€ΠΆΠ΄Π°Ρ‚ΡŒ: пСрСсадки ΠΏΠΎΡ‡Π΅ΠΊ ΠΎΡ‚ АВ0-нСсовмСстимых Π΄ΠΎΠ½ΠΎΡ€ΠΎΠ² ΠΈΠΌΠ΅ΡŽΡ‚ ΠΏΡ€Π°Π²ΠΎ Π½Π° сущСствованиС

    Noninterceptive method to measure longitudinal Twiss parameters of a beam in a hadron linear accelerator using beam position monitors

    No full text
    A new method of measuring of the rms longitudinal Twiss parameters of a beam in linear accelerators is presented. It is based on using sum signals from beam position monitors sensitive to the longitudinal charge distribution in the bunch. The applicability of the method is demonstrated on the superconducting section of the Oak Ridge Spallation Neutron Source linear accelerator. The results are compared to a direct measurement of the bunch longitudinal profiles using an interceptive bunch shape monitor in the linac warm section of the same accelerator. Limitations of the method are discussed. The method is fast and simple, and can be used to obtain the initial parameters for the longitudinal matching in linear accelerators where interceptive diagnostics are not desirable
    corecore